首页> 外文期刊>Revista do Colégio Brasileiro de Cirurgies >Conduta terapêutica atual no adenocarcinoma da cárdia e da jun??o esofagogástrica
【24h】

Conduta terapêutica atual no adenocarcinoma da cárdia e da jun??o esofagogástrica

机译:the门和食管胃交界处腺癌的当前治疗方法

获取原文
           

摘要

Adenocarcinomas of the cardia and gastroesophageal junction are peculiar entities with three different origins, which differ somewhat from other adenocarcinomas of the stomach in their clinical presentation and pathogenesis, and have a poorer prognosis. In this article the authors reviewed definitions, incidence and epidemiology, etiologic factors, genetic implications, clinical presentation, diagnosis, staging and treatment, with emphasis on the surgical approach, discussing the current management of these cancers. The prognostic factors related specifically to the cardia cancers are: esophageal invasion greater than 3cm, microscopic residual tumor and wall penetration (>T2). Preoperative workup should include computed tomography, and endoscopic ultrasonography and laparoscopy when available. Preoperative recognition of T3/ T4/N2 lesions should indicate inclusion in neo-adjuvant protocols whenever possible. The authors present the results of 46 resected cases of adenocarcinomas of the cardia and GE junction of the Instituto Nacional do Cancer- Brazil (1981-1995). Cure was intended in 29 and palliation in 17 patients. The most common type of resection was total gastrectomy with abdominal esophagectomy (28 cases). Morbidity (major and minor) occurred in 50% of the patients. The main causes were of respiratory origin and fistulas (19.6% each). Death occurred in 44% of the patients with fistula. Postoperative death until the 30th day occurred in 17.24% of the curative cases and in 23.52% of the palliative ones. The median survival time was 68.5 months for stage I, 25 months for stage II, 31 months for stage III and 12.5 months for stage IV diseases. The median survival time was 8 months for palliation and 28.5 months for cure. No long-term survival was obtained with the palliative group, whereas 25% survived five years of more in the curative group. The authors conclude that the surgical approach should be the one the surgeon feels more comfortable with. Complete removal of the disease proved by frozen section, splenectomy and D2 lymphadenectomy should be the standard therapy with curative intent.
机译:the门和胃食管交界处的腺癌是具有三个不同起源的特殊实体,在临床表现和发病机理上与其他胃腺癌有所不同,并且预后较差。在本文中,作者回顾了定义,发病率和流行病学,病因,遗传意义,临床表现,诊断,分期和治疗,重点是手术方法,讨论了这些癌症的当前治疗方法。与the门癌特别相关的预后因素是:食管浸润大于3cm,镜下残留的肿瘤和壁穿透性(> T2)。术前检查应包括计算机断层扫描,内镜超声检查和腹腔镜检查。术前对T3 / T4 / N2病变的识别应表明尽可能纳入新辅助方案。作者介绍了巴西国立癌症研究所the门和GE交界处46例腺癌切除病例的结果(1981-1995年)。治愈29例,缓解17例。最常见的切除类型是全胃切除加腹部食管切除术(28例)。在50%的患者中发生了发病率(主要和次要)。主要原因是呼吸系统起源和瘘管(每例19.6%)。瘘管患者中有44%死亡。直到30天,治愈率分别为17.24%和23.52%。 I期的中位生存时间为68.5个月,II期为25个月,III期为31个月,IV期为12.5个月。缓解的中位生存时间为8个月,治愈的中位生存时间为28.5个月。姑息治疗组未获得长期生存,而治愈组则有25%生存了五年以上。作者得出的结论是,手术方法应该是使外科医生感到更舒服的一种方法。经冰冻切片,脾切除术和D2淋巴结清扫术证明完全清除疾病应为具有治愈目的的标准治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号